WuXi Biologics Singapore CRDMO Hub Achieves Modular Topping-Out of Drug Product Facility
WuXi Biologics (2269.HK), a global leader in Contract Research, Development and Manufacturing Organization (CRDMO) services, has announced the completion of the topping out ceremony for its Drug Product (DP) facility at its Singapore CRDMO Hub. The milestone marks significant progress in the development of one of the company’s most strategically important global manufacturing sites, designed to expand its end-to-end biologics production capabilities and strengthen supply chain resilience for global pharmaceutical partners.
Once fully operational, the Singapore Drug Product facility will serve as a key manufacturing site within WuXi Biologics’ global network, supporting the production of a wide range of injectable biologic medicines. The facility is expected to deliver an annual output of approximately 100 million units, including pre-filled syringes and vials. This large-scale capacity is intended to meet the growing global demand for biologic therapies while adhering to the most stringent international regulatory and quality standards.
The facility is located within a 13.5-hectare site in Tuas Biomedical Park, a major biopharmaceutical manufacturing hub in Singapore. The CRDMO Hub is designed as a first-of-its-kind integrated site for WuXi Biologics in the region, built on the company’s proprietary technology platforms and advanced manufacturing capabilities. It will provide dual-sourcing solutions for global biopharmaceutical companies, enabling greater supply chain flexibility and risk mitigation across clinical development and commercial production stages.
The Drug Product facility itself spans approximately 30,000 square meters and is designed using a modular architecture to support scalable and flexible manufacturing operations. It will include advanced production lines capable of handling multiple dosage forms, including both liquid and lyophilized products. The site will house three pre-filled syringe (PFS) filling lines and two vial filling lines, enabling the production of sterile injectable medicines across clinical and commercial supply requirements.
In addition to manufacturing capabilities, the facility will integrate centralized Quality Control (QC) laboratories and Manufacturing Science and Technology (MSAT) laboratories. These integrated functions will support full product release testing, stability studies, process optimization, and technical lifecycle management. By combining manufacturing and scientific support functions within a single site, the facility is designed to enhance operational efficiency, improve quality oversight, and accelerate time-to-market for biopharmaceutical products.
Sustainability has also been incorporated into the design and construction of the facility. The site will feature green technologies such as solar energy systems and advanced energy monitoring and analytics infrastructure. These systems are intended to reduce environmental impact, improve energy efficiency, and support WuXi Biologics’ broader commitment to sustainable manufacturing practices across its global operations.
Operations at the Singapore Drug Product facility are expected to commence in 2027, following completion of construction, validation, and regulatory readiness activities. Once fully operational, the site will significantly expand WuXi Biologics’ global Drug Product capacity and further enhance its ability to support multinational pharmaceutical and biotechnology partners with integrated manufacturing solutions.
Dr. Chris Chen, Chief Executive Officer of WuXi Biologics, emphasized the strategic importance of the milestone, noting that the topping out of the Singapore CRDMO Hub represents another key step in strengthening the company’s global manufacturing footprint. He highlighted that the facility will enhance WuXi Biologics’ ability to provide biopharmaceutical companies with a resilient, geographically diversified supply chain supported by world-class quality systems, advanced technology platforms, and operational excellence.
Dr. Chen also underscored the company’s commitment to contributing to the development of Singapore’s biopharmaceutical ecosystem. He noted that the Singapore CRDMO Hub is not only a manufacturing expansion but also a long-term investment in local industry capabilities, talent development, and scientific innovation. The facility is expected to play an important role in supporting Singapore’s position as a leading global biopharmaceutical manufacturing center.
Beyond the Drug Product facility, construction activities across the broader Singapore CRDMO Hub continue to progress. The site will also include a Drug Substance (DS) facility, which is currently in the design phase. Once completed, the integrated hub will provide end-to-end capabilities spanning drug substance manufacturing, drug product formulation, fill-finish operations, and quality control, offering a fully connected production ecosystem for biologic medicines.
The Singapore expansion represents a key component of WuXi Biologics’ long-term global strategy to build a highly diversified and flexible manufacturing network. The company’s global footprint currently spans China, the United States, Ireland, Germany, and Singapore, with 24 Drug Substance facilities and 18 Drug Product facilities in operation worldwide. This extensive network enables the company to provide integrated, dual-sourcing manufacturing solutions that support both clinical development and commercial-scale production for biologic therapies.
A central feature of WuXi Biologics’ strategy is its ability to offer seamless integration between Drug Substance and Drug Product manufacturing. This end-to-end capability allows biopharmaceutical partners to streamline development timelines, reduce supply chain complexity, and improve manufacturing consistency across different stages of drug development. The Singapore CRDMO Hub is designed to further enhance this integrated model by bringing advanced production technologies and quality systems into a single, strategically located facility.
As of 2025, WuXi Biologics has demonstrated strong regulatory compliance across its global manufacturing network. The company has successfully passed 46 regulatory inspections worldwide, including 22 conducted by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These inspections have resulted in a 100% success rate, with no critical findings and no data integrity issues reported. This track record reflects the company’s emphasis on stringent quality standards and robust regulatory compliance across all its operations.
The completion of the Singapore facility’s structural topping out marks a visible milestone in the ongoing development of one of WuXi Biologics’ most advanced manufacturing sites. As construction progresses toward completion, the facility is expected to become a critical component of the company’s global supply network, supporting the production of next-generation biologic therapies for markets worldwide.
In the broader context of the global biopharmaceutical industry, demand for biologic medicines continues to grow rapidly, driven by advances in areas such as oncology, immunology, rare diseases, and chronic conditions. This growth has placed increasing pressure on manufacturing capacity and supply chain resilience, particularly for sterile injectable products such as monoclonal antibodies and other complex biologics.
WuXi Biologics’ investment in the Singapore CRDMO Hub reflects a strategic response to these trends, positioning the company to meet rising global demand while offering flexible, high-quality, and geographically diversified manufacturing solutions. By expanding its capacity and strengthening its global footprint, the company aims to reinforce its role as a key partner to the global biopharmaceutical industry.
As the Singapore CRDMO Hub moves toward operational readiness in 2027, it is expected to play an increasingly important role in supporting global access to biologic therapies, enhancing supply chain stability, and advancing the development and commercialization of innovative medicines worldwide.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs.
By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
